A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
Advanced Hepatocellular Carcinoma (HCC)
DRUG: OSI-906|DRUG: Placebo
Time to progression (TTP), Time from randomization to radiological disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, 20 months
Overall Survival (OS), Date of randomization until the documented date of death, 23 months|Progression Free Survival (PFS), Time from randomization to radiological disease progression based on RECIST version 1.1 assessed by investigator or death due to any cause whichever occurs first, 23 months|Time to Progression (including clinical progression) (TTPc), Time from randomization to progression (either radiological disease progression based on RECIST version 1.1 or symptomatic clinical progression as assessed by investigator), 23 months|Disease Control Rate (DCR), Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria, 23 months|Overall Response Rate, Proportion of patients with a best overall response of CR or PR based on RECIST version 1.1 criteria, 23 months|Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC), 23 months|Progression Free Survival in patients with HBV and/or HCV, 23 months|Overall Survival in patients with HBV and/or HCV, 23 months|Overall Response Rate in patients with HBV and/or HCV, 23 months|Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events, 23 months
Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to receive either single agent OSI-906 or placebo